Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1
SGNB6A-001
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
- NCT04389632 ↗
- Recruiting
- Seagen, a wholly owned subsidiary of Pfizer
- Focused
We haven't built an HCP commentary report on SGNB6A-001 (sigvotatug vedotin, pembrolizumab and 2 more in Carcinoma, Non-Small Cell Lung) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on SGNB6A-001 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase 1 Study of Sigvotatug Vedotin in Advanced Solid Tumors
- Phase
- Phase 1
- Status
- Recruiting
- Conditions
- Carcinoma, Non-Small Cell Lung; Squamous Cell Carcinoma of Head and Neck; HER2 Negative Breast Neoplasms; Esophageal Squamous Cell Carcinoma; Esophageal Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma; Ovarian Neoplasms; Cutaneous Squamous Cell Cancer; Exocrine Pancreatic Adenocarcinoma; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Stomach Neoplasms
- Interventions
- sigvotatug vedotin; pembrolizumab; cisplatin; carboplatin
- Arms
- Part A: Dose escalation · Experimental
- Part B: Dose expansion · Experimental
- Part C: sigvotatug vedotin combination therapy in NSCLC, HNSCC, ESCC · Experimental
- Part D: sigvotatug vedotin combination therapy in 1L NSCLC · Experimental
- Part D: sigvotatug vedotin combination therapy in 1L HNSCC · Experimental
- Enrollment
- 1,006 (estimated)
- Primary outcomes
- Number of participants with adverse events (AEs)
- Number of patients with laboratory abnormalities
- Number of participants with dose-limiting toxicities (DLTs)
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Start
- Jun 8, 2020
- Primary completion
- Jun 16, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT04389632 · updated Jul 6, 2026
Publications
linked from the registry- Lyon RP, Jonas M, Frantz C, Trueblood ES, Yumul R, Westendorf L, Hale CJ, Stilwell JL, Yeddula N, Snead KM, Kumar V, Patilea-Vrana GI, Klussman K, Ryan MC. SGN-B6A: A New Vedotin Antibody-Drug Conjugate Directed to Integrin Beta-6 for Multiple Carcinoma Indications. Mol Cancer Ther. 2023 Dec 1;22(12):1444-1453. doi: 10.1158/1535-7163.MCT-22-0817. PubMed 37619980